These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1850 related articles for article (PubMed ID: 31397996)

  • 1. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid Nanoparticle Systems for Enabling Gene Therapies.
    Cullis PR; Hope MJ
    Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
    Kulkarni JA; Cullis PR; van der Meel R
    Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the role of helper lipids in lipid nanoparticle formulations of siRNA.
    Kulkarni JA; Witzigmann D; Leung J; Tam YYC; Cullis PR
    Nanoscale; 2019 Nov; 11(45):21733-21739. PubMed ID: 31713568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanoparticle delivery systems for siRNA-based therapeutics.
    Wan C; Allen TM; Cullis PR
    Drug Deliv Transl Res; 2014 Feb; 4(1):74-83. PubMed ID: 25786618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
    Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
    J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA?
    Tam YK; Madden TD; Hope MJ
    J Drug Target; 2016 Nov; 24(9):774-779. PubMed ID: 27588674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-Generation Lipids in RNA Interference Therapeutics.
    Rietwyk S; Peer D
    ACS Nano; 2017 Aug; 11(8):7572-7586. PubMed ID: 28727419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery.
    Sun D; Lu ZR
    Pharm Res; 2023 Jan; 40(1):27-46. PubMed ID: 36600047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver-directed drugs for transthyretin-mediated amyloidosis.
    Brannagan TH; Berk JL; Gillmore JD; Maurer MS; Waddington-Cruz M; Fontana M; Masri A; Obici L; Brambatti M; Baker BF; Hannan LA; Buchele G; Viney NJ; Coelho T; Nativi-Nicolau J
    J Peripher Nerv Syst; 2022 Dec; 27(4):228-237. PubMed ID: 36345805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid nanoparticle technology for therapeutic gene regulation in the liver.
    Witzigmann D; Kulkarni JA; Leung J; Chen S; Cullis PR; van der Meel R
    Adv Drug Deliv Rev; 2020; 159():344-363. PubMed ID: 32622021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
    Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
    Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia.
    Connerty P; Moles E; de Bock CE; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.